About

Senior research fellow, Andreas Kupz, has embarked on a biological arms race to develop an effective life-long vaccine for tuberculosis (TB) in the face of steadily growing drug resistance to the disease.

The current vaccine, BCG, (Bacille Calmette-Guérin), only protects children. Dr Kupz is working to genetically enhance BCG to protect adults as well.

Andreas studied Biology at Humboldt University in Berlin, then moved to Australia, where he obtained an Endeavour International Postgraduate Scholarship to undertake his PhD at the Department of Microbiology and Immunology at The University of Melbourne.

His PhD study on immunity to invasive salmonellosis, in the context of AIDS-induced immunosuppression, identified a new pathway that leads to immunity to the infection. It garnered him a Dean’s award in 2011, as well as publication in respected journals such as Nature Immunology and the Proceedings of the National Academy of Sciences (PNAS).

In 2013, a fellowship from the National Health Medical Research Council (NHMRC) took him back to Berlin to equip himself with the skills required to launch an ambitious new research project at AITHM – finding a more effective vaccine for TB.

He spent three years at the Max Planck Institute for Infection Biology, one of the world’s leading TB research institution, before returning to Australia to launch the AITHM research group, Tuberculosis Immunology, funded by an NHMRC Career Development Fellowship.

A 2018 JCU Rising Stars ECR (Early Career Researcher) Leadership Award winner and a 2020 Queensland Young Tall Poppy Science Award winner, he is currently in the pre-clinical stages of his research, which aims to develop an enhanced live recombinant strain of BCG.

He is also pursuing salmonella research, and investigating immune response to toxoplasmosis, in the context of immunosuppression. The parasitic disease is also a major cause of death in AIDS sufferers.

 

Experience
  • 2018 to present - NHMRC Career Development Fellow, Australian Institute of Tropical Health and Medicine (Cairns, Australia)
  • 2016 to 2017 - NHMRC CJ Martin Research Fellow, Australian Institute of Tropical Health and Medicine (Cairns, Australia)
  • 2015 to 2016 - Postdoctoral Research Scientist, Max Planck Institute for Infection Biology (Berlin, Germany)
  • 2013 to 2015 - NHMRC CJ Martin Research Fellow, Max Planck Institute for Infection Biology (Berlin, Germany)
  • 2011 to 2013 - Research Officer, The University of Melbourne (Melbourne, Australia)
  • 2008 to 2011 - PhD student, The University of Melbourne (Melbourne, Australia)
  • 2006 to 2007 - Research Assistant, University Hospital Charite (Berlin, Germany)
Research Disciplines
Socio-Economic Objectives
Honours
Awards
  • 2020 - Queensland Young Tall Poppy Science Award
  • 2019 - Cairns Health Research Symposium, Lightning Presentation Award
  • 2018 - James Cook University, Rising Stars ECR Leadership Award
  • 2014 - Australasian Society of Immunology International Postgraduate Travel Award to attend Keystone Symposium on tuberculosis
  • 2012 - Dean's Award for Excellence in PhD Research; Faculty of Medicine, Dentistry and Health Sciences; The University of Melbourne
  • 2011 - New Investigator Award at the 41st Australasian Society for Immunology International Conference
  • 2011 - Pfizer PhD Oration Award
  • 2011 - PhD Travel Award from the Australasian Society for Immunology
  • 2010 - Scholarship from The University of Melbourne to undertake the Graduate Certificate in Advanced Learning and Leadership
  • 2010 - Second Prize for oral presentation at the Victorian Infection and Immunity Network Postgraduate Student Symposium
  • 2009 - Melbourne Abroad Travelling Scholarship (MATS), The University of Melbourne
  • 2009 - First Poster Prize at Victorian Infection and Immunity Network Postgraduate Student Symposium
  • 2009 - Travel Grant from the American Society of Microbiology to attent the 3rd International Conference on Salmonella in Aix-en-Provence, France
  • 2008 - Endeavour International Postgraduate Research Scholarship (IPRS)
Fellowships
  • 2018 to 2021 - NHMRC Career Development Fellowship Level I
  • 2012 to 2017 - NHMRC CJ Martin Overseas Biomedical Early Career Fellowship
Memberships
  • 2019 - Co-chair of the ‘Collaboration for TB Vaccine Development (CTVD) – Live Attenuated Vaccines Group’ at the Bill and Melinda Gates Foundation
  • 2019 - Member ASI Queensland Committee
  • 2019 - Member of the Advisory Council for the 6th Global TB Forum
  • 2019 - Member of the CTVD Advisory Council
  • 2019 - Institute representative for the Special Interest Group ‘Innate Immunity’, Australian and New Zealand Society for Immunology (ASI)
  • 2011 - Australian Society for Microbiology
  • 2010 - Australasian Society for Immunology
  • 2009 to 2010 - American Society of Microbiology
Publications

These are the most recent publications associated with this author. To see a detailed profile of all publications stored at JCU, visit ResearchOnline@JCU. Hover over Altmetrics badges to see social impact.

Journal Articles
Book Chapters
More

ResearchOnline@JCU stores 52+ research outputs authored by A/Prof Andreas Kupz from 2007 onwards.

Current Funding

Current and recent Research Funding to JCU is shown by funding source and project.

National Health & Medical Research Council - Investigator Grants

Towards elimination of tuberculosis

Indicative Funding
$1,170,120 over 5 years
Summary
Tuberculosis kills more people than any other infectious disease, and approximately one third of the world's population is latently infected with Mycobacterium tuberculosis. This project aims to complete the pre-clinical development of a new tuberculosis vaccine and to reveal new correlates of protection against tuberculosis using innovative mouse models and human cohorts.
Investigators
Andreas Kupz (Australian Institute of Tropical Health & Medicine)
Keywords
Mycobacterium Tuberculosis; Indigenous; Local immunity; Bcg; Vaccination

Bill & Melinda Gates Foundation - Grant

Evaluating Next Generation Live Attenuated TB Vaccine Candidates

Indicative Funding
$2,389,557 over 4 years
Summary
A key strategic goal of the BMGF Global Heatlh TB team is to prevent M. tuberculosis infection and/or TB disease through vaccination to decrease the morbidity public health burden of this epidemic. One pillar of this strategy is to accelerate development of a robust pipeline of 'next generation' candidates. This investment will evaluate novel vaccine candidates that belong to the important platform of live, attenuated mycobacterial strains. Using a head-to-head comparison ion a standardized mouse model of TB, this invesment aims to contribute to that pipeline by identifying a lead live, attenuated mycobacterial candidate(s) for further evaluation and potential development. This head-to-head comparison includes our own vaccine candidate covered by JCU IP.
Investigators
Andreas Kupz, Roland Brosch, Daria Bottai, Christophe Guilhot and Sung Jae Shin (Australian Institute of Tropical Health & Medicine, Institut Pasteur, Universita degli Studi di Pisa, Institute of Pharmacology and Structural Biology and Yonsei University)
Keywords
Mycobacterium tuberculosis; Bcg; Vaccine Development; Immunology; Infectious disease

National Health & Medical Research Council - Ideas Grants

A rationally designed vaccine for tuberculosis

Indicative Funding
$1,371,593 over 5 years
Summary
Tuberculosis kills more people than any other infectious disease, and approximately one third of the world's population is latently infected with Mycobacterium tuberculosis. Reactivation of latent tuberculosis is associated with immunosuppressive conditions, most notably AIDS and type 2 diabetes. This project aims to investigate correlates of protection against tuberculosis in these immunosuppressive conditions by using innovative mouse models and human samples and to develop a new TB vaccine.
Investigators
Andreas Kupz in collaboration with Matt Field, Denise Doolan, Emma McBryde, Daniel Judge, Roland Brosch and Anca Dorhoi (Australian Institute of Tropical Health & Medicine, Queensland Health, Institut Pasteur and Friedrich Loeffler Institute)
Keywords
Mycobacterium tuberculosis; AIDS; Bcg; Vaccination; Type 2 Diabetes

VALIDATE - Pump-Priming Grant

Evaluation of BCG?BCG1419c:ESAT6-PE25SS in immunocompetent and immunocompromised mouse models of TB

Indicative Funding
$98,016 over 1 year
Summary
Tuberculosis (TB) is a major public health concern that causes more than 1.5 million deaths each year. Vaccination is considered one of the most effective ways to eliminate TB. However, the only licensed TB vaccine, called BCG, provides limited protection against the disease in adults and can cause dangerous side effects in people with weaker immune systems. This project aims to investigate whether a new vaccine candidate can induce a stronger immune response and better protection against tuberculosis in mice with normal immune systems and is well-tolerated in mice with compromised immune systems, when compared with the original BCG vaccine.
Investigators
Ana Maria Valencia Hernandez, Socorro Miranda-Hernandez, Guangzu Zhao, Andreas Kupz and Mario Alberto Flores-Valdez (Australian Institute of Tropical Health & Medicine and CIATEJ)
Keywords
Mycobacterium Tuberculosis; Vaccine Development; Immunology; Bcg; Infectious deseases

National Institute of Health - National Institute of Allergy and Infectious Diseases

Deciphering the immune mechanisms of novel TB vaccine candidates in preclinical models of active disease and latent Mycobacterium tuberculosis infection

Indicative Funding
$448,428 over 2 years (administered by Rutgers the State University of New Jersey - New Brunswick)
Summary
Tuberculosis kills more people than any other infectious disease, and approximately one third of the world's population is latently infected with Mycobacterium tuberculosis. New vaccines are needed. These vaccines should be safe and effective against various forms of tuberculosis. This project aims to combine a new mouse model of latent tuberculosis with distinct rabbit models of TB to develop and test new vaccines against TB.
Investigators
Subbian Selvakumar and Andreas Kupz (Rutgers the State University of New Jersey - New Brunswick and Australian Institute of Tropical Health & Medicine)
Keywords
Mycobacterium Tuberculosis; Bcg; Vaccine Development; Immunology; Infectious disease

Tropical Australian Academic Health Centre Limited - Research Assistance Scheme

Unravelling novel immune parameters that correlate with BCG vaccination in humans.

Indicative Funding
$20,000 over 1 year
Summary
Tuberculosis (TB) is a leading infectious cause of death globally and is over-represented in Indigenous people in Far North Queensland. The only licensed TB vaccine, Bacille Calmette? Guerin (BCG), which is universally used to prevent TB in children, fails to protect against pulmonary TB in adults, and it is not known why protection wanes in adolescence. This project aims to unravel the immunological correlates that correlate with BCG-mediated protection in humans. Using high-dimensional immune profiling and microbiome analyses we will compare immune responses to BCG vaccination with Mycobacterium tuberculosis infection in children in the FNQ/Torres Strait region.
Investigators
Andreas Kupz in collaboration with Daniel Judge and J'Belle Foster (Australian Institute of Tropical Health & Medicine and Queensland Health)
Keywords
Mycobacterium Tuberculosis; Mycobacteria; Vaccine Development; Immunology; Infectious disease; BCG; Bacille Calmette? Guerin

Lipotek - Contract Research

TB vaccination-challenge study.

Indicative Funding
$47,579 over 1 year
Summary
This project will test the efficacy of new tuberculosis vaccine formulations developed by Lipotek Pty Ltd in a small animal model of tuberculosis at JCU.
Investigators
Andreas Kupz in collaboration with Socorro Miranda-Hernandez (Australian Institute of Tropical Health & Medicine)
Keywords
Mycobacterium Tuberculosis; Mycobacteria; Vaccine development; Immunology; Infectious disease

Far North Queensland Hospital Foundation - Research Grant

Unravelling the correlates of protection against tuberculosis ? Stage II

Indicative Funding
$50,000 over 3 years
Summary
Tuberculosis is a major global public health problem and continues to cause significant morbidity and mortality due to the low efficiency of the only licensed anti-tuberculosis vaccine, BCG. This project aims to unravel the immunological correlates that mediate protection against tuberculosis. Using high-dimensional immune profiling and microbiome analyses we will compare immune responses to BCG vaccination with Mycobacterium tuberculosis infection in children in the Torres Strait.
Investigators
Andreas Kupz in collaboration with Emma McBryde and Severine Navarro (Australian Institute of Tropical Health & Medicine and QIMR Berghofer)
Keywords
Mycobacterium Tuberculosis; Vaccine development; Microbiome; Immunology; BCG (Mycobacteria); Infectious disease

Far North Queensland Hospital Foundation - Research Grant

Preclinical evaluation of phytocompounds as novel antimicrobial agents.

Indicative Funding
$5,000 over 2 years
Summary
Through previous work funded by a FNQ Hospital Foundation Grant (JCU-QLD-838341), we have discovered two novel phytocompounds from tropical medicinal plants that show broad-spectrum antimicrobial properties against drug resistant bacterial strains that affect FNQ. To progress the development of these compounds into potential antibiotics, further pre-clinical in vitro and in vivo testing is required.
Investigators
Phurpa Wangchuk and Andreas Kupz in collaboration with Visai Muruganandah (Australian Institute of Tropical Health & Medicine and College of Medicine & Dentistry)
Keywords
Biologically active molecules; Novel drug leads; Antimicrobial agents; Isolation of compounds; Tropical medicinal plants; Wet Tropics

National Health & Medical Research Council - Career Development Fellowship

New strategies for improved tuberculosis vaccines

Indicative Funding
$437,034 over 4 years
Summary
Tuberculosis is a major global public health problem and continues to cause significant morbidity and mortality due to the low efficiency of the only licensed anti-tuberculosis vaccine, BCG. This project aims to produce novel, highly efficacious vaccination regimens against tuberculosis, especially pulmonary tuberculosis, which is currently the most difficult manifestation of infection to control. The results of this project have the potential to not only save millions of lives in the developing world but also to decrease socioeconomic burden of tuberculosis, particularly in the context of HIV co-infection.
Investigators
Andreas Kupz (Australian Institute of Tropical Health & Medicine)
Keywords
Mycobacterium Tuberculosis; HIV; Vaccine Development; Immunology; Infectious Disease

National Health & Medical Research Council - Project Grant

New strategies for improved tuberculosis vaccines

Indicative Funding
$741,092 over 5 years
Summary
Tuberculosis is one of the most threatening infectious diseases worldwide due to the low efficiency of the only licensed anti-tuberculosis vaccine, BCG. This project aims to interrogate two previously neglected immune mechanisms and their potential to enhance vaccine-induced immunity by incorporating these mechanisms into new genetically modified BCG strains. We will also investigate alternative BCG vaccination routes to generate long-lived immune cells that can rapidly control the infection.
Investigators
Andreas Kupz in collaboration with Stefan Kaufmann and Roland Brosch (Australian Institute of Tropical Health & Medicine, Max Planck Institute for Evolutionary Anthropology and Institut Pasteur)
Keywords
Mycobacterium tuberculosis-Mycobacteria; Vaccine Development; Immunology; Infectious Disease Control
Supervision

Advisory Accreditation: I can be on your Advisory Panel as a Primary or Secondary Advisor.

These Higher Degree Research projects are either current or by students who have completed their studies within the past 5 years at JCU. Linked titles show theses available within ResearchOnline@JCU.

Current
  • Shaping of intestinal T cells by physiological microbial diversification, and consequences for colorectal cancer (PhD , Secondary Advisor)
  • Antimicrobial Properties of Molecular Isolates from Tropical Flora and Fauna (PhD , Secondary Advisor)
  • Understanding Immunogenicity, Safety and Protective Efficacy of next-generation Vaccines for Tuberculosis (PhD , Primary Advisor/AM/Adv)
  • Understanding Immunity to Tuberculosis for the Rational Design of Improved Vaccines (PhD , Primary Advisor)
  • Does Oxidative Stress drive the Evolution of Drug-resistant (DR) Mycobacterium Tunerculosis (Mtb) within the Infected Macrophage? (Masters , Secondary Advisor)
  • Airway Resident Memory T Cell Development and Persistence: The Key to Induction of Sterile Immunity against Pulmonary Tuberculosis? (PhD , Primary Advisor)
Completed
Collaboration

The map shows research collaborations by institution from the past 7 years.
Note: Map points are indicative of the countries or states that institutions are associated with.

  • 5+ collaborations
  • 4 collaborations
  • 3 collaborations
  • 2 collaborations
  • 1 collaboration
  • Indicates the Tropics (Torrid Zone)

Connect with me
Share my profile
Share my profile:
jcu.me/andreas.kupz

Email
Phone
Location
Advisory Accreditation
Primary Advisor
Find me on…
Icon for Scopus Author page

Similar to me

  1. Dr Socorro Miranda-Hernandez
    Australian Institute of Tropical Health & Medicine
  2. Dr Saparna Pai
    Australian Institute of Tropical Health & Medicine
  3. Dr Ana Maria Valencia Hernandez
    Australian Institute of Tropical Health & Medicine
  4. Dr Harindra Sathkumara Mudiyanselage
    Australian Institute of Tropical Health & Medicine
  5. Prof Emma McBryde
    Australian Institute of Tropical Health & Medicine